ORSERDU 86 mg film-coated tablets, LETROZOLE , -, ORSERDU 345 mg film-coated tablets, Kisqali 200 mg film-coated tablets, EXEMESTANE , ANASTROZOLE
ABCSG 63
Phase 2 small_molecule active
Quick answer
ORSERDU 86 mg film-coated tablets, LETROZOLE , -, ORSERDU 345 mg film-coated tablets, Kisqali 200 mg film-coated tablets, EXEMESTANE , ANASTROZOLE for endocrine-responsive HER2-negative early breast cancer is a Phase 2 program (small_molecule) at Rein Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Rein Therapeutics
- Indication
- endocrine-responsive HER2-negative early breast cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active